INSPIRE IVF Public Company LimitedSET: IVF🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

INSPIRE IVF Public Company Limited

Telephone

0-2251-8666

Website

www.inspireivf.com

Email

ivf@inspireivf.com

Dividend Policy

Dividend Policy

The Company will consider dividend payments based on its profitability in each year and overall operating results, subject to applicable legal requirements, and will refrain from dividend payments in the event of accumulated losses. The Company has a policy to pay dividends to shareholders of not less than 50 percent of net profit based on the separate financial statements, after deduction of corporate income tax, statutory reserves, and other reserves (if any). In determining dividend payments, consideration will be given to the Company’s financial position, cash flow, liquidity, investment plans, and other factors as deemed appropriate by the Board of Directors. Dividend payments shall not materially affect the Company’s normal business operations. Dividend payments shall be approved by the Board of Directors and proposed for approval at the shareholders’ meeting, except for interim dividend payments, which may be approved by the Board of Directors and reported to the shareholders’ meeting at the next meeting.

Dividend payments shall not exceed the retained earnings as shown in the separate financial statements of the Company and shall be made in accordance with applicable laws.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescription
-0.040.070.1911.18-5.72Net profit per share (Baht : Share)Net profit per share (baht : share)
00.061300Dividend per share (Baht : Share)Dividend per share (baht : share)
0000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
00.0613Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
096.6649.17Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Introduction

Information as of December 30, 2028

Major Shareholders

No.NameShares% Shares
24,321Mr. Chanachai Joonjiraporn142,810,60032.46
24,322Mr. Puttipong Poomsuwan52,400,80011.91
24,323Ms. Kasinee Kuldiloke29,700,0006.75
24,324Mr. Bandit Anantamongkol18,594,2004.23
24,325MR.PEERAPONG JIRASEVIJINDA9,950,0002.26
24,326Ms. Sumalee Ongjarit7,332,1001.67
24,334Air Chief Marshal Auwetchai Jaengreo6,708,7001.52
24,335Mr. NAWAT TANASETTAKORN6,431,8001.46
24,336Mr. VISUT PORAMAPORNPILAS6,200,5001.41
24,337Mr. KIATCHAI KUNAKORNKUL5,000,0001.14

Remark

Appendix: 1.3.4 Shareholders – List of the Top 10 Shareholders as of December 30, 2024 and December 30, 2025

Business Strategies Overview

Chairman's Message

Message from the Chairman of the Board and Chief Executive Officer

Dear Shareholders,

On behalf of the Board of Directors, the Management Team, and all employees of Inspire IVF Public Company Limited, we are honored to present this report to our shareholders. In 2025, despite global and domestic economic volatility and challenges arising from various external factors—including lifestyle changes and demographic shifts that have led to declining birth rates both in Thailand and worldwide—the demand for fertility services has continued to grow. This is largely due to the trend of later marriages and family planning at older ages, making infertility a significant health concern that people around the world are willing to invest in to build complete and quality families. Within this context, 2025 marked a year of “laying the foundation” for sustainable and long-term growth of Inspire IVF Group.

The Company has consistently strengthened its core fertility technology business while preparing organizational structures, systems, and capabilities to capture new business opportunities aligned with our expertise and long-term vision. A key milestone in 2025 was the establishment of a subsidiary named “M22,” designed as a strategic mechanism to expand the Group’s business and investment portfolio. Its purpose is to identify and develop high-growth opportunities that can generate long-term value, particularly in healthcare-related businesses and other sectors consistent with the Group’s direction and capabilities. This initiative supports our risk diversification strategy and the creation of stable new revenue streams. The Company remains committed to prudent investment decisions, effective risk management, and operating under sound corporate governance principles.

In our core business, we continue to uphold high medical standards and treatment quality. In 2025, our pregnancy success rate rose to 76%, significantly above the national average of 52%. This achievement reflects the expertise of our medical team, scientists, and multidisciplinary professionals, as well as our investments in advanced laboratories and specialized technologies. We believe these results reinforce patient confidence that choosing Inspire IVF is truly an investment in hope with a strong chance of success.

Looking ahead, the Company has set strategic goals to expand the Thai patient base from approximately 10–20% to 30%, while maintaining and growing our international clientele. We also plan to expand into high-purchasing-power international markets, beginning with the Middle East in the United Arab Emirates (UAE), where operations are expected to commence in the second quarter of 2026. This will establish a crucial foundation for building an international network of fertility centers. In addition, the Company is integrating Telemedicine and Artificial Intelligence (AI) into treatment and management processes to enhance medical efficiency, elevate patient experience, and optimize resource management. These initiatives will enable us to serve a growing number of patients while maintaining quality standards and patient-centered care.

Inspire IVF is evolving beyond the role of a “specialized fertility clinic” to become a “comprehensive health and technology provider” serving both Thai and international clients. We aim to create a new growth curve through our “X-PanSe Framework,” which consists of four key pillars:

  • X-Tech: Integrating advanced medical technologies, laboratories, digital platforms, and AI to enhance quality, standards, and treatment efficiency.

  • X-Health: Expanding comprehensive healthcare services, including Fertility, Preventive & Regenerative Medicine, and related services, through organic growth, joint ventures, or acquisitions.

  • X-Tourism: Collaborating with partners in tourism, hospitality, and related services to promote Wellness & Fertility Tourism, positioning Thailand and Inspire IVF as global health destinations.

  • X-Capital: Managing capital strategically with discipline and efficiency to support domestic and international growth, while maintaining financial stability and delivering sustainable returns to shareholders.

Throughout the execution of these strategies, the Company prioritizes corporate governance, risk management, and responsibility to all stakeholders, with “patients and families” at the center of our service design, technology investments, and business expansion. Our growth is intended to be balanced—across business, social, and value dimensions—delivering meaningful impact to people.

On behalf of the Board of Directors and Management, Inspire IVF Public Company Limited extends our sincere gratitude to shareholders, clients, partners, medical institutions, business allies, and all stakeholders for their trust and continued support. Your confidence is the driving force behind our commitment to organizational development. We reaffirm our mission to “create hope, create life, and create completeness for families”—not only for those seeking to have children, but also in contributing to Thailand’s advancement in fertility technology and healthcare services at the international level. We sincerely hope that our shareholders will continue to join us on this important journey of growth.

Sincerely yours,

-Pornthep Anussornnitisarn- -Kasinee Kuldiloke-

(Assit.Prof.Dr. Pornthep Anussornnitisarn) (Ms. Kasinee Kuldiloke)

Chairman of the Board Chief Executive Officer

Vision

Asia's leader in comprehensive infertility treatment, aiming to create happiness for clients and their families. With a reliable, intelligent, and caring approach, we provide simple and convenient services under international standards for you and your loved ones in the future.

Mission

Advanced Care Technology
To utilize advanced technologies to enhance success rates in fertility treatment and support the healthy growth of your loved ones in the future.

Expert Team Excellence
To bring together a team of fertility specialists, including physicians, scientists, customer care professionals, and coordinators, working closely together to deliver excellent care and services.

Care with Compassion
To be a trusted partner for our patients throughout their journey, upholding the highest ethical standards and promoting sustainable growth.

Objectives

- To be a provider of high-quality infertility treatment.

- To be a leading provider of infertility treatment.

- To be a highly capable company expanding in the global market.

Goals

- To be a provider of quality infertility treatment with internationally accredited hospitals and laboratories and medical/scientific/medical technologist personnel with leading capabilities in Asia.

- To be a leading provider of infertility treatment in Thailand and Asia by providing efficient services that satisfy customers and conducting business ethically.

- Create sustainable growth in the IVF business and related or potential businesses both now and in the future, as follows:

  • IVF Business: The company will focus on building brand awareness, developing skills and technology, maintaining international quality of care, and becoming a business leader in Asia. The company aims to expand its IVF business both domestically and/or internationally by 2 branches within 3 years.

  • Related or Potential Businesses: To increase revenue streams, the company will expand into related or potential businesses. The company will select profitable targets. The company has a variety of business expansion approaches, such as investing in the entire target company or forming joint ventures with potential partners.

Business Strategies

1. Continuous development of service quality through skilled personnel and investment in modern technology to increase the success rate of pregnancy.

The Company remained committed to the continuous enhancement of service quality, with a strong focus on both talent recruitment and development, as well as investment in advanced medical technologies. These efforts aimed to elevate treatment standards and improve pregnancy success rates for patients. In terms of human resources, the Company recruited experienced fertility specialists, scientists, nurses, customer relations officers, and supporting staff who possess the appropriate expertise, capabilities, and service-oriented mindset, aligned with the Company’s “INSPIRE” organizational culture. As of the reporting period, the Company employed one full-time fertility specialist with over 20 years of experience in reproductive medicine, along with six part-time physicians, all highly specialized professionals who collaborated with the Company on an agreed schedule. For embryology and genetic testing personnel, the Company maintained a team of five full-time scientists, including two certified embryologists. With respect to technology and infrastructure investments, the Company invested in 3D and 4D ultrasound systems to enhance the precision of detecting abnormalities within the uterine cavity. In addition, the Company constructed an internationally certified embryology laboratory (Clean Room Class 10,000) and invested in a closed-system embryo incubation device (Embryoscope Plus), which utilizes artificial intelligence (AI) to monitor embryo development and assess embryo quality (grading). Furthermore, the Company invested in embryo genetic testing technology using the SNP Array technique and received official confirmation from the authorized distributor of Illumina reagents that the Company is the only fertility treatment center in Thailand officially utilizing Illumina’s SNP Array technology. This technique enables whole-genome scanning with high-throughput analytical capability, allowing for the detection of chromosomal abnormalities in both number and structure, as well as single-gene disorders through karyomapping. Such capabilities help reduce the risk of transmitting genetic disorders from parents to offspring, including thalassemia, cystic fibrosis, and sickle-cell anemia. The Company also expanded its holistic healthcare (wellness) approach through investment in Double Filtration Plasmapheresis (DFPP) technology, which supports immune system balance, reduces inflammation, and promotes overall health of couples—an important factor contributing to successful pregnancy outcomes.

As a result of these operations, the company expects an average pregnancy success rate for its users of 70-76% by 2025, which is higher than the overall pregnancy success rate of 52% in Thailand, as announced by the Department of Health Service Support, Ministry of Public Health. In customer service operations, the Company deployed qualified customer service personnel with strong coordination capabilities, service-oriented attitudes, and effective communication skills. These personnel are able to communicate in multiple languages, including English and Chinese, and possess an understanding of the fertility treatment business to efficiently support international patients. In addition, the Company encouraged continuous professional development across all employee levels through participation in training programs and seminars covering professional expertise, emerging technologies, compliance with international standards, and good corporate governance practices, such as risk management and greenhouse gas management. These initiatives were undertaken to ensure workforce readiness in driving the Company toward sustainable growth in line with its established vision.


2. Provision of Comprehensive Fertility Treatment Services under Internationally Recognized Standards.

In addition to infertility treatments using ICSI and IUI, the Company provided a range of alternative services to accommodate the diverse treatment needs of patients. These services included fertility preservation through the cryopreservation and storage of oocytes, sperm, or embryos; testicular sperm extraction; preimplantation genetic testing of embryos; and the application of regenerative medicine to support physiological balance. These services were provided to enable comprehensive and individualized infertility treatment solutions.

With respect to operational standards, the Company placed importance on the continuous study, monitoring, and implementation of internationally recognized standards in its operations. In particular, the Company focused on healthcare quality standards accredited at the international level by the International Society for Quality in Healthcare (ISQua), to improve operational processes and foster patient confidence.

The Company was the first fertility treatment center in the Asia region to receive accreditation from the American Accreditation Commission International (AACI). This international accreditation encompasses International Healthcare Standards as well as ISO : 9001 and EN standards concurrently. In addition, the Company received the Excellent Award: Outpatient IVF Specialist Center, becoming the first and currently the only recipient within the IVF business sector in the Asia-Pacific region. AACI standards are widely recognized across Europe, the Americas, and the Middle East. AACI is also one of three international organizations with which the Department of Health Service Support, Ministry of Public Health, has entered into a cooperation agreement to develop Thailand’s medical service quality system and health and medical tourism in accordance with international standards. Furthermore, the Company received accreditation for fertility treatment services from Temos International Healthcare Accreditation, Germany, which is an international organization accrediting quality of care and patient safety in accordance with international medical standards that supports the development and excellence of medical treatment and healthcare service delivery for healthcare providers worldwide.

As a result of these operations, patients of the Company were able to receive infertility treatment services, including both core and alternative services, under internationally accredited service standards certified by globally recognized institutions.


3. Building Awareness and Recognition of the Company’s Brand and Identity through Effective Communication.

The Company commenced its operations as a fertility treatment center under the concept of “Luxury and Relax,” with a focus on providing services that are of quality, convenient, cost-effective, and responsive to patient needs, under internationally recognized service standards. Accordingly, the Company placed importance on creating a comprehensive patient experience across multiple dimensions. These included the design of patient areas to resemble the atmosphere of premium hotel lounges; the design of the Company’s logo depicting a couple and an infant within a heart shape to reflect the nature of its services and its vision of fulfilling family happiness; and the systematic cultivation of the “INSPIRE” organizational culture throughout the Company.

Patients were able to place confidence in the management and service delivery under the INSPIRE brand, whereby services of quality, value, and international standards were provided by personnel across various professional disciplines. Such personnel were recruited and developed in a structured manner in accordance with the Company’s organizational standards before 2020. The Company conducted marketing communications through both online and offline channels. For online channels, the Company utilized its website and Facebook as primary communication platforms. For offline channels, the Company organized academic meetings in collaboration with business partners, participated in international seminars, and engaged customer coordinators or referrers to introduce the Company’s services to target customer groups in various countries. Such referrers were required to understand the Company’s vision and accept the terms and conditions for collaboration to deliver services to customers. As a result of offline communication activities, the proportion of international patients in 2019 exceeded that of domestic patients. However, due to the outbreak of the COVID-19 pandemic in 2020, which affected international travel, the Company increased its online communication activities on an ongoing basis. At present, the Company communicates through various digital channels, including:

Website: https://www.inspireivf.com/en/home

YouTube: https://www.inspireivf.com/th/home

TikTok: https://www.tiktok.com/@inspireivfclinic

Facebook: https://www.facebook.com/inspireivfthailand

Instagram: https://www.instagram.com/inspireivf

The Company established communication guidelines and formats to ensure consistency across all channels, to build awareness and recognition of the INSPIRE brand as a fertility treatment center providing quality, value-based, and comprehensive services under internationally recognized service standards.

The Company has also continuously developed its service approach to accommodate international patients, including designing service processes that facilitate convenience before, during, and after treatment. This includes implementing a telemedicine system (in 2025, the Company is in the process of developing the system and preparing for the relevant operating license).

4. Creating Growth through Collaboration with Potential Domestic and International Partners.

The Company pursued a growth strategy through collaboration with business partners to support marketing activities, enhance operational efficiency, and improve service quality. The Company’s key business partners included the following:

  • Customer coordinators, both domestic and international, who introduced the Company’s services to target customer groups in various countries and provided insights into customer needs. Such information enabled the Company to design treatment approaches and service delivery that were appropriate for individual patients.

  • Healthcare providers or laboratories, both domestic and international, that served as partners for the exchange of academic knowledge, new technologies, and practices related to infertility treatment. These collaborations contributed to the development of the Company’s service quality. In addition, such partners acted as referrers of patients to the Company and jointly explored business opportunities during the period.

The Company conducted its collaboration with business partners based on principles of integrity, responsibility, and professionalism. As a result, the Company continued to receive cooperation from its partners in joint business operations. Having a network of capable partners both domestically and internationally enabled the Company to access beneficial information across various areas, including academic knowledge, technology, service trends, and approaches to expanding the customer base. These factors supported the Company’s growth during the period.

5. Growth Strategy under the “X-PANSE” Concept

The Company’s participation in the SET’s JUMP+ program, together with 2025 being a foundational year for the Company, has led to the development of a growth strategy framework under the “X-PANSE” concept. This framework represents a multidimensional expansion approach (Multidimensional Expansion Framework) designed to support the Company’s long-term growth. The strategy encompasses development across four key dimensions: (1) Technology (X-Tech) to enhance service efficiency and treatment success rates; (2) Integrated Healthcare Services (X-Health) to expand holistic patient care; (3) Medical Tourism (X-Tourism) to accommodate and expand the international patient base; and (4) Partnership Network (X-Network) to increase business opportunities and access to new customer segments.

The X-PANSE strategy will be implemented in the Company’s operations in the next phase (Roadmap 2026–2028) to support sustainable growth going forward (further details are provided in the Appendix).

Material Changes & Developments

Material Changes & Developments

YearDescription
2,018

March: Inspire IVF Co., Ltd. was established in 2018 with a registered capital of 65.00 million baht.
July: : The company commenced operations by renting space at Ploenchit Center to be used as a clinic providing consultation services from family planning to various treatment methods to help couples conceive as desired.

November: The registered capital was increased to 90.00 million baht to purchase tools and equipment for business operations, such as ultrasound machines, sterile IVF cabinets, and microscopes.

2,019

March: Participated in The Infertility Conference at YiWu Minimally Invasive Surgery Hospital in the People's Republic of China to present knowledge and exchange academic expertise on infertility treatment.

June: Attended The 35th Annual Conference of the European Society of Human Reproductive and Embryology in Austria to study infertility treatment technologies.

2,020

The COVID-19 pandemic has spread globally, including in Thailand, resulting in travel restrictions. People worldwide are unable to travel internationally, consequently preventing the company's international customers from accessing its services.

2,021

March : Achieved international standards for health tourism management in the program specifically for COVID-19 (GHA COVID-19 Guidelines for Medical Travel Program) from GHA.

May : Certified to ISO9001 and AACI (American Accreditation Commission International) standards, a system of international quality assurance from the United States. AACI is a standard that helps enhance the quality of service locations in terms of safety for service users, accurate and clear treatment, from consultation, treatment, dispensing medication, and aftercare (follow-up). It ensures correct procedures, standardized equipment, and personnel quality.

2,022

The COVID-19 pandemic began to subside, allowing international customers to travel and utilize the company's services.

The company started recruiting additional personnel and implementing the Green ERP system to enhance work system efficiency and prepare for listing on the Stock Exchange of Thailand (SET).

2,023

May and December : Invested in DFPP machines to provide rehabilitation medicine services. June-July: Restructured capital by reducing registered capital from 90.00 million baht to 75.00 million baht, with a par value of 100.00 baht per share, to offset accumulated losses and increase registered capital to 105.00 million baht to be used as working capital for the company.

September : Transformed into Inspire IVF Company Limited (Public)

: Increased registered capital to 155.00 million baht, with a par value of 100.00 baht per share, to be used as working capital.

2,024

March: Changed the par value of shares from 100.00 Baht per share to 0.50 Baht per share. Increased registered capital from 155.00 million Baht to 220.00 million Baht by issuing 130.00 million additional common shares at a par value of 0.50 Baht per share to be offered to the public.

April: Participated in The 20th Shanghai International Medical Tourism Fair in the People's Republic of China with the Tourism Authority of Thailand to promote and introduce health tourism in Thailand.

August: Invested in a closed embryo culture system (Embryoscope Plus) that uses AI to track and grade embryos. Also invested in a semen analysis machine that uses AI to select sperm and grade.

: Received accreditation for fertility care services from Temos International Healthcare Accreditation, a German healthcare accreditation body, in both Quality in reproductive care and Excellence in international reproductive care.

December: Listed on the Market for Alternative Investment (MAI).

2,025

M22 Company Limited was established with a registered capital of 1,000,000 baht, with the objective of investing in other potential businesses.

Use of Proceeds from Securities Offerings

Introduction

Inspire IVF Public Company Limited (IVF) issued and offered ordinary shares by Initial Public Offering (IPO) from November 29 to December 3, 2024, totaling 130,000,000 shares at the offering price of 3.10 Baht per share and received proceeds of 388 million baht after deducting expenses incurred from the offering.

IVF would like to report on the results of using the additional capital received from the initial public offering (IPO) ending on December 31, 2025,as follows:

Is There Money Raised from a Securities Offering Still to Report On?

Yes

Offerings

Type of SecuritiesAmount Raised Given AsAmount Raised (Million Baht)Uses of the MoneyUsed as Declared?Progress / Reasons and Measures if Not Used as DeclaredRelated Link
Equity Instruments28733882026-12 · Objective: For use as working capital · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 41.62 · Expected amount type: 2873 · Start expected amount range: 158.0 · 2026-12 · Objective: For use as investment in branch expansion · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 3.12 · Expected amount type: 2873 · Start expected amount range: 50.0 · 2026-12 · Objective: For use as an investment in related businesses, such as overall wellness service businesses, etc. · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 15.75 · Expected amount type: 2873 · Start expected amount range: 30.0 · 2026-12 · Objective: For use as investment in other businesses with potentials · Period type: 2871 · Start period: 2026-12 · Spent amount type: 2873 · Start spent amount: 2.31 · Expected amount type: 2873 · Start expected amount range: 150.0N

The company has an operational plan to maximize the benefits of using IPO funds. After reviewing additional information obtained following the study of investment models and allocation ratios, the company found that the amount for each purpose is higher than currently needed. Moreover, the company does not need to invest all the funds raised from the IPO, and it can still manage these investments with reduced capital. The company has received approval from the 2025 Annual General Meeting of Shareholders to change the objectives for the use of IPO funds as follows.


Use of Proceeds

Previous Use of Funds

Current Use of Funds

Approximate Amount Received from IPO (Millions of Baht)

Percent

Used Amount (Millions of Baht)

Remaining IPO Amount Before Change (Millions of Baht)

Remaining IPO Amount After Change (Millions of Baht)

Percent

Approximate Timeframe for Use

For use as working capital

84.00

21.65

-

84.00

158.00

40.72

Within 2026

For use as investment in branch expansion

190.00

48.97

-

190.00

50.00

12.89

Within 2026

For use as investment in related businesses, such as overall wellness service businesses etc.

114.00

29.38

-

114.00

30.00

7.73

Within 2026

For use as investment in other businesses with potentials

-

-

-

-

150.00

38.66

Within 2026

Total

388.00




388.00

100.00


https://www.set.or.th/en/market/news-and-alert/newsdetails?id=100905900&symbol=IVF

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

Investment Policy and Governance of Subsidiaries and Associated Companies

Inspire IVF Public Company Limited (the “Company”) has established a policy for the governance and oversight of the operations of its subsidiaries and associated companies. Accordingly, the nomination of, and the exercise of voting rights for, the appointment of directors of subsidiaries and associated companies (in the case of associated companies, only those directors representing the Company) are required to obtain prior approval from the Company’s Board of Directors. Persons appointed as directors of subsidiaries or associated companies are required to perform their duties in the best interests of such subsidiaries or associated companies, and not in the best interests of the Company. In addition, the Company requires that such appointed persons obtain prior approval from the Company’s Board of Directors before voting or exercising voting rights on any material matters of subsidiaries or associated companies that are of the same level of significance as matters that would require approval from the Company’s Board of Directors if undertaken by the Company itself. The appointment of representatives to serve as directors of subsidiaries and associated companies shall be made in proportion to the Company’s shareholding and/or in accordance with shareholders’ agreements of such subsidiaries and associated companies.

Furthermore, in the case of subsidiaries, the Company requires that persons appointed by the Company ensure that such subsidiaries properly and completely comply with the applicable rules and regulations of the Office of the Securities and Exchange Commission and/or the Stock Exchange of Thailand in respect of connected transactions, the acquisition or disposal of assets, and other material transactions. Such subsidiaries are also required to apply disclosure requirements and transaction criteria in a manner consistent with those of the Company. In addition, the appointed persons are required to oversee proper data retention and accounting records of the subsidiaries to enable the Company to review and consolidate such information for the timely preparation of consolidated financial statements in accordance with the requirements of the Stock Exchange of Thailand.

Companies Where the Company Holds ≥10%

Introduction

At the meeting of the Board of Directors of Inspire IVF Public Company Limited No. 1/2025 held on February 28, 2025, the Board of Directors resolved to approve the establishment of one (1) new subsidiary, with the details as follows:

Company Name: M22 Company Limited

Date of Establishment: March 10, 2025

Registered Capital: Baht 1,000,000 (one million Baht), divided into 10,000 ordinary shares (ten thousand shares) with a par value of Baht 100 (one hundred Baht) per share

Objective: To invest in other businesses with potential

Shareholding Structure: Inspire IVF Public Company Limited holds 99.96% of the total shares

Board of Directors: Mr. Chanachai Joonjiraporn, Ms. Kasinee Kuldiloke, Mr. Puttipong Poomsuwan, and Mr. Bandit Anantamongkol

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneBusiness TypeSecurity TypeSharesPaid-up Shares
M22 COMPANY LIMITEDPloenchit Centre Floor 5th, Room Number 05 - 10B, Sukhumvit Soi 2, KlongtoeyBangkok10110+66 (2) 251-8666Invest in other businesses that have potential.Common shares10,00010,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

Yes

Description

- Apart from guaranteeing credit facilities with leasing companies, the Company has no significant relationship or involvement in other businesses of its major shareholders.

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
M22 COMPANY LIMITEDINSPIRE IVF Public Company Limited · Voting rights percent: 99.96 · Shareholding proportion percent: 99.96

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations69,868.73100108,344.43100122,094.84100
Infertility Treatment Business61,726.9388.3599,037.391.41107,903.288.38
Regenerative Medicine147.820.216,6656.1513,644.911.18
OtherOthers7,993.9811.442,642.132.44546.740.44

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue69,868.73100108,344.43100122,094.84100
DomesticDomestic69,868.73100108,344.43100122,094.84100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 7993.98 · Description: Total other income · As of yesteryear: 2642.13 · As of year before yesteryear: 546.74 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 7993.98 · Description: Other income not from operations · As of yesteryear: 2642.13 · As of year before yesteryear: 546.741713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0

Product / Service Characteristics

Business Type

3114

Business Groups

Business GroupDescription
Infertility treatment services

Key Business Strengths of the Company are as follows:

  • The Company is among the first fertility centers in the Asia-Pacific region to obtain internationally recognized accreditations, including AACI and ISO 9001, reflecting its high-quality services and globally aligned operational standards.

  • The Company is a pioneer in providing telemedicine services for fertility treatment in the ASEAN region, enhancing accessibility and convenience for both domestic and international patients.

  • The Company has been selected to participate in the SET Jump+ program, which supports high-potential listed companies with strong growth prospects.

  • The Company has applied Artificial Intelligence (AI) technology in embryo analysis and selection to improve treatment success rates.

  • The Company has a diverse international customer base across India, the Middle East, and ASEAN, supporting long-term revenue growth.

The Company operates infertility treatment centers serving both Thai and international patients experiencing fertility challenges. Services are provided by specialists in reproductive medicine and supported by internationally accredited embryology laboratories. The key services include:

1. Infertility Treatment Services

1.1 Infertility Treatment through ICSI (Intracytoplasmic Sperm Injection)

ICSI is a form of assisted reproductive technology involving in vitro fertilization. It is recognized as having a higher success rate compared to other treatment methods. This procedure is suitable for cases where the male partner has a low sperm count, abnormal sperm morphology, or sperm that cannot penetrate the egg naturally; where the female partner has abnormalities in the fallopian tubes; or where couples carry genetic disorders that may affect maternal health during pregnancy or the health of the child. It is also applicable for couples seeking preimplantation genetic screening to reduce the risk of genetic abnormalities and increase the likelihood of a successful pregnancy.

The ICSI process involves collecting sperm from the male partner and eggs from the female partner, selecting a single healthy sperm, and injecting it directly into an egg to facilitate fertilization. The resulting embryo is cultured in an incubator within a Clean Room environment, where air particles, temperature, humidity, sound, lighting, and air pressure are strictly controlled to meet international standards. Once a viable and healthy embryo is developed, it is transferred into the uterus for further growth and development.

1.2 Other Infertility-Related Services

In addition to ICSI, the Company offers other infertility-related services as optional packages with additional costs. These include:

  • Preimplantation Genetic Testing (PGT)

    The Company provides genetic testing services for embryos as follows:

    1. PGT-A (Aneuploidy) using Next Generation Sequencing (NGS) to detect abnormalities in chromosome numbers, which may lead to genetic disorders.

    2. PGT-SR (Structural Rearrangement) using SNP Array technology to identify abnormalities in chromosome numbers and structural rearrangements. Such abnormalities are often associated with infertility, recurrent miscarriages, or implantation failure. This method provides high-throughput, detailed analysis.

    3. PGT-M (Monogenic Disorder) using Karyomapping to detect gene-level abnormalities. This reduces the risk of transmitting genetic diseases from parents to offspring. The technique is highly detailed, covers multiple conditions, and delivers rapid results, making it suitable for couples who are carriers of genetic disorders or have a family history of such conditions.

    4. Fertility Preservation

      Cryopreservation of eggs, sperm, or embryos in liquid nitrogen at -196oC. This process preserves the quality of reproductive cells at the age they were collected, maintaining their effectiveness for future use.

    5. Percutaneous Epididymal Sperm Aspiration / Testicular Sperm Extraction (PESA/TESE)

      Direct sperm retrieval from the testes or epididymis for cases where the male partner has issues with sperm production or ejaculation.

    6. Intrauterine Insemination (IUI)

      A treatment method involving the injection of prepared sperm directly into the uterus during ovulation to increase the chances of fertilization.

Preventative and Regenerative Medicine Services for the General Public ("Regenerative Medicine")

2. Preventive and Regenerative Medicine Business The Company operates a business in preventative and regenerative medicine (Wellness), which focuses on holistic healthcare. Services include physical examinations for assessment and analysis, vitamin supplementation, and treatments to restore health deterioration and rebalance the body. These services are tailored to each individual to ensure that bodily functions operate effectively. At present, the Company provides two main types of services:

2.1 Double Filtration Plasmapheresis (DFPP) A process designed to purify blood by using specialized filters selected according to the specific conditions of each patient. This treatment helps restore health and rebalance the body.

2.2 Vitamin and Hormone Supplementation: A service that provides vitamins and nutrients to improve skin health and support hormonal balance. Each treatment is based on individualized assessment and diagnosis to ensure appropriateness and alignment with the specific needs of each patient

Research & Development

Has R&D Policy (Y/N)

No

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

0.0

R&D Cost — Last Year

0.0

R&D Cost — 2 Years Ago

0.0

Assets Used in the Business

Permanent Assets — Description

Fixed assets

Item

Ownership

Encumbrances

Book Value (Million Baht)

1. Building

Lease

-

-

2. Leasehold improvements and office furnishings

Ownership

None

25.07

3. Office Equipment

Ownership

None

0.84

4. Medical tools and equipment

Ownership

None

20.74

Total

46.65

Right-of-use assets

The Company entered into a lease agreement for office space at Ploenchit Center with Prime Office Leasehold Property Fund (“the Fund”). The current lease agreement is dated March 21, 2024, with a lease term from July 1, 2024, to June 30, 2027. However, the Fund’s land lease, on which the Ploenchit Center building is situated, will expire on January 23, 2025, which is earlier than the expiration date of the Company’s current building lease agreement. Subsequently, the Fund and the landowner jointly executed a notification letter with the Company regarding the transfer of lease rights and building services of Ploenchit Center, informing the Company of the transfer of all rights and obligations of the Fund, in its capacity as lessor and service provider, to the landowner upon the expiration of the Fund’s land lease. In addition, the Company received a letter from the landowner confirming the intended use of the Ploenchit Center building as an office building and agreeing that the Company may lease the premises for business operations until 2034. The Company used this information in determining the useful life of the right-of-use asset. As of December 31, 2024, the Company recognized a right-of-use asset, namely the lease of office space at Ploenchit Center, with a net carrying amount of Baht 59.19 million, and as of December 31, 2025, the net carrying amount was Baht 53.19 million.

Intangible Assets — Description

  1. Computer software had a net carrying amount of Baht 2.33 million.

  1. The Company entered into lease agreements for premises, equipment, and related services for Unit No. 05-10B on the 5th floor of the Ploenchit Center Building, with a total usable area of 957.92 square meters, for a lease term of three years from July 1, 2024, to June 30, 2027.

  2. The Company entered into agreements for the appointment of referral agents, whereby coordinators were appointed to refer customers to receive medical treatment and medical services from the Company for contract periods ranging from one to two years, with compensation payable as a percentage of service fees or at agreed amounts.

  3. The Company obtained property insurance policies covering risks to its assets, including furniture, fixtures and fittings, office equipment, machinery and equipment, utility systems, medical equipment, pharmaceutical inventories, and other related assets located at the insured premises, for a coverage period of one year from October 6, 2025 to October 5, 2026, with a total insured sum of Baht 80 million.

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

Investment

The Company has a policy of investing in subsidiaries and joint ventures with the potential to grow and generate strong returns, which may be businesses that support the Company's core businesses or other promising businesses. Such investments must be appropriate and consistent with the Company's business conditions, strategic plans, and the rules and regulations of the regulatory authorities.

The Company will focus on long-term investments by considering the fundamentals and trends of the businesses to be invested in and investing in appropriate proportions to enable participation in the management and determination of the business direction of such subsidiaries and joint ventures, including promoting the growth of the invested businesses sustainably.

The Company will consider investments and proceed with caution and prudence by conducting feasibility analyses of investment plans, taking into account risks, returns, the Company's financial liquidity, and the country's economic conditions. Investment plans will be submitted to the Board of Directors for approval. The Company will establish a system for monitoring, following up on, and reporting on investments to the Board of Directors regularly.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Pricing Policy

Pricing of Infertility Treatment Services

The Company adopts a pricing policy based on cost plus an appropriate gross profit margin (Cost Plus Margin). In determining service fees, the Company considers various factors, such as the cost of providing services, customer referral costs, as well as the service fees charged by other operators, in order to maintain competitiveness.

The Company focuses on providing services that are of quality, cost-effective, and comprehensive in meeting customer needs in accordance with international standards. With regard to payment channels for service fees, the Company has arranged various payment methods, including cash, credit cards, and transfers. The currency accepted for payment is Thai Baht. However, as the Company’s main customer group consists of foreign customers, the cost of payment of service fees is therefore subject to foreign exchange risk and payment processing fees. Cash payment, which the Company considers to be the method with the lowest cost for both customers and the Company, is therefore the payment method most commonly used by customers at present. The Company accepts service fee payments in Thai Baht only. The Company has clearly defined procedures and responsible persons for depositing cash with banks. Such procedures must be carried out accordingly, and supporting evidence must be presented to the Accounting Manager or the Chief Accounting and Finance Officer in accordance with the Company’s prescribed practices.


Characteristics of Target Customer Groups

The Company’s customers consist of both domestic and foreign customers, which can be classified as follows:

1. Married couples experiencing infertility Infertility refers to married couples who intend to have children and have regular sexual intercourse at least twice per week without contraception for a period of 12 months but are unable to conceive (in accordance with the diagnostic criteria set out in the Clinical Practice Guidelines of the Royal Thai College of Obstetricians and Gynecologists on infertility care). The causes of infertility may include stress, fast-paced lifestyles, work-related factors, or physical abnormalities, which may arise from female factors, such as blocked fallopian tubes or endometriosis, or male factors, such as low sperm count or obstructed vas deferens, or a combination of factors from both parties. However, infertility in married couples may involve multiple contributing causes, which may also include geographical factors affecting physiology or cultural factors of each country that may affect genetics. Therefore, attending physicians must thoroughly assess these causes and consider appropriate treatment on a case-by-case basis.

2. Customers planning to have children in the future This group consists of customers who do not wish to have children at present but intend to preserve their fertility for future childbearing through fertility preservation, including cryopreservation for the storage of oocytes, sperm, or embryos. In general, oocyte cryopreservation is more commonly utilized than sperm cryopreservation, as women have a more limited age range for obtaining good-quality oocytes compared to men. Oocyte cryopreservation is therefore suitable for women who are not yet ready to become pregnant, particularly those aged over 35 years, as well as women who are required to undergo medical procedures that may affect the quantity and quality of oocytes or the reproductive system.

3. Customers seeking body enhancement and balance This group consists of health-conscious customers who seek longevity free from illness or wish to maintain a good physical appearance. In cases where the body experiences functional issues or age-related degeneration, physicians will recommend appropriate vitamins and hormones on an individual basis, using examination results as reference data. Such treatments help enhance the body’s ability to recover and repair itself. In addition, the Company provides plasma filtration services using specialized filters to help reduce inflammatory levels in the body by lowering blood lipid levels, including cholesterol and triglycerides.

As the Company focuses on providing services in accordance with international standards and implements growth strategies through collaboration with potential overseas partners, the majority of the Company’s customers in the past have been foreign customers. The proportion of foreign customers, such as those from China and India, accounted for approximately 91.16 percent, while Thai customers accounted for approximately 8.84 percent. The main service utilized by customers was infertility treatment, which accounted for approximately 99.75 percent of service revenue for the year 2025.


Sales and Distribution Channels

1. Direct customer contact, including the presentation of products and services through both offline and

online channels, as follows:

  • offline channels, such as organizing academic meetings with business partners and participating in various

seminars and introducing services at the clinic.

channels, such as YouTube, TikTok, Facebook, and Instagram.

2. Customer contact through coordinators/referral agents, whereby the Company enters into appointment agreements with referral agents to introduce the Company’s services to target customers in various countries. As of 31 December 2025, the Company had a total of 23 customer coordinators providing referral services in various countries. The Company has clearly defined the qualifications and compensation of agents, with compensation rates set at levels that are competitive within the industry. The Accounting and Finance Department is required to submit a summary report on referral fee payments to the Audit Committee on a quarterly basis. In cases where a referral agent is a related party of a director or an executive, the Company requires disclosure of the name of such referral agent and the relationship with the relevant director or executive. To date, the Company has not paid commissions to any coordinator in excess of the prescribed policy. In addition, the Company stipulates that referral agents must not be employees of companies engaged in the IVF business similar to that of the Company, must not have conflicts of interest, and must have experience as a broker or relevant experience related to the Company’s business, in order to prevent the appointment of referral agents from being used as a channel for the transfer of benefits that could adversely affect the Company.

Industry & Competition (Overall)

Overview of the Global Infertility Market

The global infertility treatment industry continues to expand steadily, driven by changes in demographic structure and consumer behavior, particularly the trend of individuals marrying and having children at a later age. This has resulted in a significant increase in demand for assisted reproductive technologies. In addition, advancements in medical technologies—such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing of embryos—have contributed to higher treatment success rates and strengthened patient confidence.

Based on industry studies, the global infertility treatment market is expected to continue growing and is projected to reach more than USD 33.6 billion by 2030, with a relatively high compound annual growth rate. This reflects the long-term growth potential of the industry, particularly in the Asia-Pacific region, which represents a high-growth market1.

Fertility Medical Tourism in Thailand

Thailand is considered one of the countries with strong potential to become a regional hub for infertility treatment services in Asia. This is supported by internationally recognized medical service standards, highly experienced medical professionals, and competitive treatment costs compared to developed countries2.

In addition, Thailand is well-equipped with comprehensive infrastructure and supporting services in both healthcare and tourism sectors, enabling it to consistently attract international patients. Key customer groups include patients from China, India, and the Middle East, which are high purchasing-power markets with increasing demand for fertility-related services2. Following the recovery of the tourism industry after the COVID-19 pandemic, inbound demand for medical services in Thailand has continued to grow, which is consistent with the Company’s customer base, where approximately 91 percent of total customers are foreign nationals3.

Demand Trends in the IVF Business

Demand for assisted reproductive technologies, particularly in vitro fertilization (IVF), continues to grow due to several factors. These include societal changes where individuals prioritize education and careers, resulting in delayed childbearing, as well as aging populations and declining birth rates in many countries4.

In terms of patient structure, couples experiencing infertility remain the primary customer segment of the industry. At the same time, segments seeking future family planning—such as egg freezing—and individuals with a focus on health and preventive care are steadily increasing5.

Moreover, patients are placing greater emphasis on treatment quality and success rates. This has led service providers to continuously enhance technologies and service standards, including the adoption of advanced technologies such as genetic screening and the application of artificial intelligence (AI) in treatment processes to improve efficiency and accuracy6.

In addition, cross-border treatment remains a key driver of industry growth, as patients tend to seek countries that offer high medical standards and reasonable costs, which supports the long-term expansion of operators in Thailand2.

Demand Trends in IVF as a Medical Tourism Hub

The demand for assisted reproductive technologies, particularly IVF, continues to increase globally, in parallel with the growth of medical tourism. Patients are increasingly traveling across borders to receive treatment in countries with high medical standards and relatively reasonable costs compared to their home countries1.

In the context of Thailand, which has the potential to serve as a fertility treatment hub in Asia, demand from international patients is expected to grow significantly. This is supported by factors such as high-quality medical services, internationally recognized healthcare standards, and the expertise of medical professionals, combined with competitive treatment costs compared to developed countries2.

Furthermore, demographic changes in many countries—particularly key target markets such as China, India, and the Middle East—show a trend toward later marriage and childbearing, resulting in increased demand for fertility services. In addition, legal or regulatory restrictions in some countries also encourage patients to seek treatment abroad3.

From a consumer behavior perspective, patients increasingly prioritize treatment success rates, technology used, and integrated service offerings covering the entire patient journey—from consultation and treatment to post-treatment care. This has become a critical factor in selecting healthcare providers, prompting operators to continuously enhance technologies and service standards4.

Finally, the recovery of the global tourism industry following the COVID-19 pandemic continues to support the growth of the IVF business within the medical tourism segment. Thailand maintains competitive advantages in terms of geographic location, infrastructure readiness, and its reputation for service quality, all of which support long-term business expansion5.

Source: As detailed in the Appendix.

From 2025 onwards, the infertility treatment center business in Thailand and globally has shown a continuous growth trend, driven by several factors, including demographic changes, advances in medical technology, and social trends that place greater importance on having children at a later age. At the same time, the population structure of Thailand and many countries worldwide is shifting toward an aging society, with a declining population of reproductive age and birth rates falling below the replacement rate, which has become a significant issue that governments need to urgently address. As a result, demand for alternative fertility services, such as intracytoplasmic sperm injection (ICSI) and intrauterine insemination (IUI), is expected to increase. In addition, the lifestyle of the younger generation, which places greater emphasis on work and building economic stability rather than starting a family at a young age, has led to later marriages and family planning at the age of 30–40 years. This is a period during which fertility in both women and men declines significantly, making reliance on assisted reproductive technologies unavoidable. Although demand for such services continues to increase, the business still faces several challenges. One of the key challenges is intense competition from both existing and new service providers. Currently, Thailand has several well-known infertility treatment centers, each with its own strengths, whether in terms of physicians’ experience, technologies used, success rates, or initial pricing strategies aimed at improving accessibility. In addition, competition at the international level is another important factor to consider, particularly from neighboring countries such as Singapore and Malaysia, which actively promote medical tourism and have several internationally accredited infertility treatment centers.

If Thailand is to maintain its competitiveness, support measures from the government will be necessary, including tax reductions for healthcare businesses, support for research activities, and concrete promotion of Thailand as a regional hub for infertility treatment in Asia. Another significant challenge is rising operating costs, including living expenses, labor costs, and the cost of medical equipment, most of which must be imported from abroad. As a result, service centers are required to plan and manage costs efficiently. At the same time, consumers have higher expectations regarding service quality, technology, and success rates, which requires infertility treatment centers to invest in new technologies, such as the use of artificial intelligence (AI) for embryo analysis and the development of embryo culture techniques to increase implantation potential.

In terms of legal and ethical aspects, many countries have begun to place greater emphasis on regulations governing assisted reproductive technologies, particularly with respect to the control of the use of reproductive cells, egg donation, and the storage of embryos in cryopreservation banks, which may affect service delivery models in the future. Therefore, if Inspire IVF aims to enhance its competitive capability, it should focus on creating differentiation, such as providing comprehensive services covering consultation, treatment, as well as psychological care and therapy for service recipients, the addition of appropriate recreational or entertainment activities, the adoption of technology to enhance the accuracy of treatment, and the development of personnel quality to achieve expertise at an international level.


In addition, the enactment of laws supporting the rights of the LGBTQA+ community has created greater growth opportunities for the medical services business, particularly IVF clinics, as same-sex couples are able to legally and more conveniently access fertility services. As a result, demand for assisted reproductive technologies, such as intracytoplasmic sperm injection (ICSI) and egg freezing, is expected to continue to increase.

Industry Analysis

1. Political Factors

In 2025, the Thai government placed importance on health and reproductive policies, with a tendency to support industries related to assisted reproductive technologies (Assisted Reproductive Technology: ART), such as in vitro fertilization (IVF) and intrauterine insemination (IUI). However, laws remain strict with respect to IVF treatment, whereby only legally married couples are permitted to access such services. This may pose obstacles for unmarried couples and LGBTQA+ couples. Nevertheless, there may be a trend toward legislative initiatives to expand access to infertility treatment, such as extending rights to LGBTQA+ couples or single individuals to access treatment through medical certification processes or through other legal mechanisms, such as the registration of civil partnerships that are recognized in certain cases, in order to circumvent existing legal restrictions.

In addition, government policies in foreign countries relating to fertility, such as China’s policy to encourage citizens to have more children (the three-child policy), may present opportunities for market expansion. In India, although birth rates remain high, middle-class individuals experiencing infertility have increasingly begun to utilize such services.

Political risks remain in the form of legal restrictions and potential changes in medical policies, such as limitations on surrogacy or regulations governing foreign nationals seeking medical services.

2. Economic Factors

Surveys indicate that the global infertility treatment market is expected to grow to a value of more than USD 33.6 billion by 2030 and is expected to grow at an average rate of 14% per year, while the Thai market is expected to grow at an average rate of 10% per year, as Thailand serves as a hub for medical tourism. With respect to the purchasing power of foreign customers, which account for 80% of Inspire IVF’s target customer base, the majority are from high-income countries such as China, India, and countries in the Middle East, where the middle-class population is expanding rapidly. This group has the ability to pay for treatment, with an average cost of approximately THB 200,000–500,000 per treatment cycle. Exchange rates and import duties on medical equipment also have an impact, as a depreciation of the Thai Baht may attract more foreign customers to seek treatment in Thailand. In addition, the importation of IVF equipment and medical supplies from Europe and the United States may result in higher costs if new import tax measures are imposed.

The economic conditions in 2025 show signs of recovery from the period following the COVID-19 pandemic, although the recovery remains limited. The working-age population with middle- to high-income levels has shown increased interest in receiving infertility treatment services. However, treatment costs remain a key obstacle, as the average cost per IVF cycle remains at approximately THB 200,000–500,000

In the future, the market is expected to grow as a result of the expansion of services to cover foreign customer groups and the development of packages that enable Thai customers to access services at more affordable prices.

3. Social & Cultural Factors

At present, the Thai population tends to marry later, and the birth rate has continued to decline. It has been found that the infertility rate in Thailand is approximately 15–20% of married couples. The trend toward later marriage has resulted in increased reliance on assisted reproductive technologies. In addition, Thai society is transitioning toward an aging society, which has led to greater interest in infertility treatment services. Moreover, working-age women increasingly opt for egg freezing to plan for having children in the future, resulting in the expansion of such services. Thai society is receptive to medical tourism, and Thai people have become more accepting of infertility treatment, particularly among highly educated groups. Going forward, it is expected that social acceptance of LGBTQA+ couples and non-traditional families will increase, which may place pressure on the government to adjust policies to enable IVF services to better accommodate these groups.

4. Technological Factors

Assisted reproductive technologies have continued to advance, such as the use of AI to assist in selecting high-quality sperm and embryos, as well as genetic testing technologies to increase pregnancy success rates. As a result, the use of AI and Big Data to analyze pregnancy prospects for individual patients is expected to increase. Further, leading to more effective treatment and a reduction in treatment costs per cycle in the future. In addition, new technologies related to IVF have been adopted to enhance the likelihood of embryo implantation.

5. Environmental Factors

Environmental factors, such as pollution, chemicals in food, and global warming, affect fertility in both men and women, resulting in a greater need for assisted reproductive technologies. In addition, the impact of environmental pollution on fertility, including air pollution and toxic substances, is also a factor contributing to infertility.

6. Legal Factors

Laws related to IVF treatment continue to stipulate that only legally married couples are eligible to receive such services, which constitutes a limitation for LGBTQA+ couples and single individuals. In addition, surrogacy laws in Thailand provide that surrogacy is permitted only for legally married couples, while commercial surrogacy is prohibited by law. As a result, couples who do not meet such criteria are required to seek alternative options, such as pursuing surrogacy services overseas. Nevertheless, there may be a trend toward legal amendments to better accommodate same-sex couples, particularly if draft legislation recognizing civil partnerships is enacted to grant medical rights equivalent to those of heterosexual married couples.

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

1. Procurement of the Company's business premises

The Company places importance on the procurement of business premises from the selection of the location. Currently, the Company's location is at 2 Ploenchit Center Building, 5th Floor, Sukhumvit 2 Alley, Khlong Toei Subdistrict, Khlong Toei District, Bangkok 10110, which is easily accessible due to its proximity to the expressway and BTS Skytrain. It is also an area well-known to foreigners, who are a key target group of the Company.

The Company designed the premises under the concept of "Luxury and Relax" to make users feel like they are in the lobby of a leading hotel, to make customers feel relaxed and receive luxurious and high-class care, worth the service. In the clinic area, there is a reception area, a registration point, and initial screening. The treatment and recovery rooms are proportionally separated to ensure that users receive safety and confidence in the Company's services.

Currently, the Company has 1 service location with an area of approximately 1,000 square meters. The Company's embryo incubator can accommodate up to approximately 1,000 customers per year. In the past, the Company has provided services at only approximately 15% of its maximum service capacity, which means there's still plenty of room to expand the services. However, this service rate is only an average figure for the entire year. In actual service, there may be periods when customers use the full capacity that the Company can accommodate, and there are periods when they use less.

In the future, if there is an expansion of service areas, the Company will consider key factors such as the convenience of access for customers and personnel who will be required to provide services, a safe and recognizable environment. The design approach will be adapted to future target customer groups, while still complying with relevant standards.

2. Procurement of medical supplies, medicines, and medical equipment

The Company places importance on the procurement of medical supplies, medicines, and medical equipment. The Company's team of physicians and scientists, who are experts, will monitor information on new and modern technologies to consider the necessity and appropriateness of procuring medical supplies, medicines, materials, tools, and equipment to enable the Company to provide services efficiently. In procuring medical tools or equipment such as ultrasound machines, embryo incubators, genetic testing machines, and DFPP machines, the Company purchases from domestic sellers who are distributors of foreign manufacturers. The Company will consider technology, features, price, and after-sales service as primary factors. In the case of instruments that require permission from the regulatory authority, tThe Company will verify relevant documents from suppliers, such as import licenses and certificates of compliance with applicable standards, including ISO, CE, or TIS, as well as approvals from the Food and Drug Administration (FDA) of Thailand, to ensure treatment effectiveness and the safety of patients receiving the Company’s services.

In the procurement of medical supplies, medicines, and laboratory reagents, which must be purchased regularly, the Company will select products that are scientifically recognized as standard, having been inspected and certified by relevant organizations such as the Department of Medical Sciences, Food and Drug Administration, WHOs or CE, and the Food and Drug Administration (FDA) in Thailand, etc. to ensure safety and efficacy in use. In cases where there is no significant difference in the properties of the products, the Company will consider the price and service of the seller. The Company will consider sellers or distributors that are reliable and reputable, appointed directly by the manufacturer or owner of the goods, and will assign a person responsible for checking the quantity of inventory to ensure that it is sufficient and not excessive. During 2022-2024 , the Company was able to procure medical supplies, medicines, and laboratory reagents sufficient for use.

The Company does not have any exclusive purchase agreements for medicines and medical supplies with any particular supplier. The Company's procurement process requires regular price comparisons and vendor evaluations. However, some medicines or medical supplies have only one distributor of foreign manufacturers, such as medicines used specifically with embryo genetic testing machines using SNP Array technology, which is a technology developed by a foreign operator. Including some medicines or medical supplies that have properties that meet the needs of doctors or scientists, the purchase of such goods is not subject to price comparison. However, there will be an assessment of the distributor's service to prepare a register of vendors that have passed the assessment each year, and there is a follow-up of new substitute products that may be added as an option for the Company.

For the year 2022-2025 , the Company does not purchase medical supplies, medicines, and medical equipment from any single seller in excess of 30 percent of the value of purchases in each year. The Company purchases products from one major seller in the proportion of approximately 20-27 percent of the value of purchases in each year. This seller is a major importer and distributor of pharmaceutical products, medical supplies, and medical equipment in the country.

3. Procurement of service personnel

Providing infertility treatment services requires the collaboration of personnel from various fields of assisted reproductive technology, including doctors, nurses, scientists, medical technicians, and customer service representatives. The Company places equal importance on personnel in each department.

In recruiting professional personnel, which includes doctors, nurses, and scientists, or medical technicians, the Company will consider and verify qualifications and professional documents correctly and completely according to the relevant regulations of the Ministry of Public Health, and have a good attitude in delivering services to customers under the Company's organizational culture. In the past, the Company has recruited personnel through recommendations from executives who have good relationships with entrepreneurs and executives in the medical business. However, at present, the Company is better known among professionals, including having more business partners, resulting in the Company being contacted by doctors, nurses, and scientists, or medical technicians to apply for jobs with the Company, especially medical personnel. However, the Company has a policy of planning its workforce to align with its business expansion plan while maintaining efficient cost management. The Company, therefore, selects doctors who wish to work with the Company on a temporary part-time basis. basis to provide additional customer service. In the past, the Company has never experienced a shortage of personnel to provide services.

For personnel in various support functions, the Company recruits those with the appropriate knowledge and abilities to undertake the responsibilities they are required to perform. For example, Customer Service personnel will be considered for their coordination skills, service-minded attitude, and communication skills. The Company's customer service staff can communicate in multiple languages, such as English and Chinese, and have an understanding of the infertility treatment business to serve foreign customers, etc.

The Company regularly evaluates and determines appropriate compensation and encourages the development of the knowledge and abilities of its personnel by participating in training or seminars both related to their profession and related to compliance with international standards or good corporate governance. There is an orientation for new employees, an annual training plan, and knowledge and experience sharing from experienced personnel (on-the-job training). It also encourages all professions to express their opinions freely and equally in order to retain talented personnel to work with the Company and attract new personnel to join the Company. In addition, the Company regularly reviews its manpower plan to ensure that it has sufficient and continuous quality personnel to provide services.

Raw Material Acquisition (Overall)

The company places great importance on sourcing pharmaceuticals, medicines, and medical equipment through its team of doctors and scientists who are experts in their fields. They monitor updates on new and advanced technologies to assess the necessity and appropriateness of procuring medical supplies, drugs, medical materials, and various tools and equipment to ensure the company can provide efficient services. When purchasing medical equipment such as ultrasound machines, incubators, genetic disorder testing devices, and DFPP machines, the company procures from domestic sellers who are authorized distributors of foreign manufacturers. The company prioritizes technology, product features, price, and after-sales service. In cases where equipment requires approval from regulatory authorities, the company will verify the relevant licenses from the seller, such as an import license for the product, as well as certifications of compliance with various standards. For the regular procurement of pharmaceuticals, drugs, and laboratory reagents used in medical laboratories, the company selects products that are scientifically recognized as meeting standards, having been inspected and certified by relevant organizations such as the Department of Medical Sciences, the Food and Drug Administration (FDA), WHO, or CE, and the Thai Food and Drug Administration (FDA) to ensure safety and effectiveness. In cases where products have no significant differences in features, the company will consider the price and service offered by the seller. The company will also consider vendors or distributors with a reputable name who are directly authorized by the manufacturer or product owner and will designate a responsible party to ensure that inventory levels are sufficient but not excessive.

Number of Raw-Material Distributors (Overall)

1

Production Capacity (Overall)

ItemUnitUnit (if Other)UsedCapacity
BedOthersbed512,000

Domestic/Overseas Purchase Proportion (Overall)

Raw MaterialSource CountryValue
Medicines and medical suppliesThailand12,596,411.2

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents